CJC-1295 Results
CJC-1295 results track on the GH/IGF-1 axis, usually alongside ipamorelin. IGF-1 is the objective confirmation; sleep and recovery are the felt effects.
Why measurement beats a before/after photo
CJC-1295 raises GH pulses, but the felt result (better sleep, recovery) is easy to attribute to placebo or other variables. IGF-1 is the objective anchor - a baseline-vs-6-week draw tells you whether the GHRH analog is actually moving your axis.
What to track on CJC-1295
A rise into the optimal range confirms the response.
Deeper sleep + vivid dreams are commonly reported.
Improved between-session recovery.
Watch for GH-driven glucose drift.
CJC-1295 timeline: what tends to shift, when
Sleep-architecture changes (deeper sleep, vivid dreams) often appear first.
IGF-1 reaches its set point - confirm with a draw.
Recovery + sleep benefits hold if the response is real.
Signal vs placebo: how to tell a real result
The DAC form means a non-daily schedule, which makes attribution sloppy without a log. The objective read is IGF-1 at baseline vs 6 weeks; the semi-objective read is a wearable sleep trend. If both moved with the compound timeline, the result is real. Sleep "feeling better" alone, with no IGF-1 baseline, is the placebo trap.
How to actually track CJC-1295 results
Track CJC-1295 + ipamorelin as one stack against a single IGF-1 timeline. Log sleep nightly, note recovery, and pull IGF-1 at baseline and 6 weeks. Because the DAC form is non-daily, the dose log is what keeps the before/after honest.
Track CJC-1295 results with MyProtocolStack →